



CEDARS-SINAI MEDICAL CENTER.

NEWS

8700 Beverly Blvd., Room 2429A ■ Los Angeles, CA 90048-1865
Office (310) 423-4767 ■ Fax (310) 423-0435

Media Contact: Johnny Hagerman
Tel. 310-423-2270
E-mail: johnny.hagerman@cshs.org

FOR IMMEDIATE RELEASE – MARCH 7, 2003

HIGHLIGHTS:

Mark Hyman Rapaport, MD, was recently named Chairman of the Department of Psychiatry and Mental Health at Cedars-Sinai Medical Center. Before coming to Cedars-Sinai, he served as Director of the Mental Health Outpatient Clinical Research Center within the Department of Psychiatry at University of California, San Diego (UCSD). With research interests focused on psychopharmacology to discover more effective treatments, Dr. Rapaport has investigated the biologic genesis of anxiety disorders, bipolar disorder, depression and immune abnormalities in schizophrenia.

CEDARS-SINAI MEDICAL CENTER'S DEPARTMENT OF PSYCHIATRY AND MENTAL HEALTH NAMES NEW CHAIRMAN

LOS ANGELES – Mark Hyman Rapaport, MD, was recently named Chairman of the Department of Psychiatry and Mental Health at Cedars-Sinai Medical Center. Before coming to Cedars-Sinai, he served as Director of the Mental Health Outpatient Clinical Research Center within the Department of Psychiatry at University of California, San Diego (UCSD).

“The department of psychiatry and mental health at Cedars-Sinai Medical center has the opportunity to become one of the premier small departments of psychiatry in the country,” says Dr. Rapaport, “The department is in a unique position to develop a wonderful synergy with the UCLA NPI and where we each can strengthen one another. Our potential in child psychiatry, addiction medicine and translational research is extraordinary.

With research interests focused on psychopharmacology to discover more effective treatments, Dr. Rapaport has investigated the biologic genesis of anxiety disorders, bipolar disorder, depression and immune abnormalities in schizophrenia.

Dr. Rapaport has served as a consultant to more than 14 pharmaceutical companies to help develop promising new drug therapies, and he has trained and mentored students, physicians and researchers in the field of psychopharmacology. He was previously first Chair of the National Institute on Drug Abuse (NIDA) Clinical Trials Network's Data Safety Monitoring Board and Chair of its Special Review Committee.

(more)

A board-certified psychiatrist, Dr. Rapaport has written over 130 articles for such peer-reviewed publications as American Journal of Psychiatry, Biological Psychiatry, Journal of Clinical Psychiatry and Neuropsychopharmacology. He is member of the American College of Psychiatrists, American Society of Clinical Psychopharmacology, Anxiety Disorders Association of America, the Psychiatric Research Society and the Collegium International Neuropsychopharmacology (CINP). He is a fellow of the American Psychological Association (APA) and the CINP.

###

For media information and to arrange an interview, please contact Johnny Hagerman via e-mail at johnny.hagerman@cshs.org or call 310-423-2270. Please note that this information is intended for members of the news media. If you have received this news release in error and do not wish to receive future advisories, or if they should be directed to someone else in your organization, please call 1-800-396-1002 so we can update our records. Alternatively, you may fax your updated information or your request for removal from our list to 808-263-3364 or e-mail it to sandy@vancommunications.com.